A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study

INTRODUCTION: Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that stimulates erythropoiesis. METHO...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Kidney Int Rep
मुख्य लेखकों: Charytan, Chaim, Manllo-Karim, Roberto, Martin, Edouard R., Steer, Dylan, Bernardo, Marializa, Dua, Sohan L., Moustafa, Moustafa A., Saha, Gopal, Bradley, Charles, Eyassu, Meraf, Leong, Robert, Saikali, Khalil G., Liu, Cameron, Szczech, Lynda, Yu, Kin-Hung P.
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Elsevier 2021
विषय:
Clinical Research
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC8258588/
https://ncbi.nlm.nih.gov/pubmed/34307977
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ekir.2021.04.007
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन